All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Deals, Development and Manufacturing
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
Global Perspectives
Intellectual Property & Patents
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
Mergers and Acquisitions
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Deals, Development and Manufacturing
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
Global Perspectives
Intellectual Property & Patents
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
Mergers and Acquisitions
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

Navigating Data Integrity in the Modern Lab

February 2, 2018
By Amber Lowry
News
Article
Pharmaceutical TechnologyPharmaceutical Technology-02-02-2018
Volume 42
Issue 2
Pages: 30

Steve Hayward, product marketing manager at BIOVIA, Dassault Systèmes, discusses the importance of both technology and people in the modern laboratory.

Understanding the role of both people and technology in the maintenance of data integrity in the analytical laboratory is crucial as companies move toward predominately electronic systems. While technology has helped make the preservation of data easier, it is just as important that the people operating these systems are aware of the relevance of each step involved in the process, says Steve Hayward, product marketing manager at BIOVIA, Dassault Systèmes. Hayward spoke with Pharmaceutical Technology about what it takes to successfully maintain the integrity of data in the modern laboratory.

PharmTech: What is most important to consider for lab data integrity?

Hayward: The people in the lab and the digital solutions they use play an equal role to ensure data integrity. Technology helps to make it easy to execute, as well as to proof integration. The technology of the past decade has allowed for better preservation of data, from the time of capture in electronic format through to its analysis and use in reports. 

This digital thread of information can now be preserved throughout an organization, but it is critical that the people who use the technology are aware of why each process step is relevant, and adhere to them at all times.  Automation is also a key factor. The best way to ensure this consistency is by making it easier and less time-consuming to perform each routine activity, while passively recording each action for regulatory compliance. This can be achieved by automation-enabling technology.

PharmTech: How can data integrity in the lab be improved by the use of electronic systems?

Hayward: Electronic data systems that automate data transfer allow for the reduction or even elimination of human intervention, and therefore, the reduction of errors. Audit trails will prove the integrity of the data or show the details of the change. This means any data alteration--voluntary or involuntary--will be either not possible, or any changes will be recorded so it will be obvious that data have been modified. 

 

PharmTech: What are the data integrity risks associated with computerized systems and how can they be diminished?

Hayward: In the modern lab, it is a fact of life that there will be multiple electronic informatics systems, where the landscape’s complexity has usually scaled with the size and age of the company.  Data are constantly passed back and forth amongst these systems, and may be transformed during the process.  At each step along the way, the process must be validated to ensure that the integrity of the data, and the digital thread of information, is preserved. Recently, the trend has been toward consolidation of these disparate systems into more comprehensive solutions, where the data are stored in a single, centralized system and accessed as needed, without the need for constant transformation and transposition. While validation is still necessary, this removes both the day-to-day complexity in the lab and much of the risk of compromised data integrity.

PharmTech: How can manipulation of electronic records be identified and prevented?

Hayward: In the lab, all data files should only be accessible through a software system which requires secure user login, and tracks all modifications as part of the audit trail. A computer’s operating system-level login is not sufficient for this purpose.  Although many solutions exist to enforce audit trails, in many cases, a user must log in to multiple different systems, sometimes more than once, just to complete a single task.  With ever-increasing regulatory requirements, routine tasks can take longer. A goal in the modern digital lab is to minimize the number of systems a scientist must use for any given tasks, which increases efficiency, centralizes the management of audit trails, and minimizes the potential for data corruption or manipulation.

PharmTech: What can companies do to improve lab data integrity when using electronic systems?

Hayward: Many paper-based processes have already been eliminated from the lab during the first wave of digital lab solutions. However, the multitude of different electronic systems in place, often from many different vendors, means that data still must be transposed and often transformed as it moves from one system to the next. Each of these steps must be configured and validated to ensure both regulatory compliance and the preservation of the data’s integrity.  Where possible, systems should be consolidated to remove the multiple different data file types and connections between software from different vendors.  It is also of the utmost importance that users are appropriately trained on the systems, and that their qualifications kept up-to-date.

Article Details

Pharmaceutical Technology
Vol. 42, No. 2
February 2018
Page: 30

Citation

When referring to this article, please cite it as A. Lowry, " Navigating Data Integrity in the Modern Lab," Pharmaceutical Technology 42 (2) 2018.

Download Issue PDF
Articles in this issue

Designing a Single-Use Biopharmaceutical Process
Designing a Single-Use Biopharmaceutical Process
Material Traceability in Continuous Pharmaceutical Tablet Manufacturing
Material Traceability in Continuous Pharmaceutical Tablet Manufacturing
Establishing Correlation Between Aerosol and Surface Microbial Populations
Establishing Correlation Between Aerosol and Surface Microbial Populations
Analyzing Content Uniformity
Analyzing Content Uniformity
Figure 1.jpg
The Power of Synchrotron X-Ray Powder Diffraction for the Characterization of Pharmaceuticals
Impurity Testing
Impurity Testing
PF701807_small-225-1.jpg
Tabletop Peristaltic Liquid-Filling Machine
Ross-Tumble-Blenders-(1,-5-and-7.5-cu.ft.)_225.jpg
Safety Light Curtain Feature on Tumble Blenders
10346-Colorcon-SGR-logo-and-Render-225.jpg
Aqueous Sugar Film Coating System
LogTag-Serie_USB_klein_225.jpg
USB Data Logger for Temperature-Sensitive Products
Navigating Data Integrity in the Modern Lab
Maintaining Lab Data Integrity
Maintaining Lab Data Integrity
Barriers to ATMP Drug Development
A New Business Model for Pharma?
Managing Risk in a Complex Excipient Supply Chain
Managing Risk in a Complex Excipient Supply Chain
Recent Videos
Industry Outlook 2025: European Geopolitical Impact on Pharma
Industry Outlook 2025: European Geopolitical Impact on Pharma
Industry Outlook 2025: Political Implications for Pharma
Industry Outlook 2025: Political Implications for Pharma
Ask the Expert: EU Data Protection
Ask the Expert: EU Data Protection
Industry Outlook 2025: The Impact of Politics on Pharma
Industry Outlook 2025: The Impact of Politics on Pharma
Industry Outlook 2025: Technology as a Supporting Element
Industry Outlook 2025: Technology as a Supporting Element
US tariff rate rising , trade policy , business graph and dollars banknote , tax calculation change | Image Credit: © janews094 - stock.adobe.com
Tariff Pause Reinforces Uncertainty Among Biopharma Professionals
Industry Outlook 2025: Talent Up for Grabs
Industry Outlook 2025: Talent Up for Grabs
INTERPHEX 2025: ‘Breaking Up the Octopus’ of Single-Use Systems
INTERPHEX 2025: ‘Breaking Up the Octopus’ of Single-Use Systems
INTERPHEX 2025: Advanced Flow Sensor Technologies Enable More Accurate Measurement
INTERPHEX 2025: Advanced Flow Sensor Technologies Enable More Accurate Measurement
Industry Outlook 2025: Evolving Pipelines and Supply Chain
Industry Outlook 2025: Evolving Pipelines and Supply Chain
Related Content
Advertisement

A laboratory technician performing a quality control test on a batch of pharmaceutical tablets, highlighting the importance of ensuring drug safety. | Image Credit: ©MAY -stock.adobe.com

Poor API Quality Threatens a Healthy Supply

Susan Haigney
May 9th 2025
Article

Poor API quality may often lead to delays in production and a shortage of supply.


Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.


Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

New CBER Director Appointed

Susan Haigney
May 7th 2025
Article

FDA chooses Dr. Vinay Prasad, MD, MPH, a hematologist-oncologist, to lead the Center for Biologics Evaluation and Research at FDA.


Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.


n-nitrosodimethylamine molecular structure, 3d model molecule, n-nitrosamines, structural chemical formula view from a microscope | Image Credit: © Сергей Шиманович - stock.adobe.com

Strategies for Mitigating Nitrosamine Risk

Susan Haigney
May 7th 2025
Article

Amit Chivate, senior market manager, Greater Asia and China, Roquette, provides his perspective on FDA’s recommendations regarding nitrosamines.


White House | Image Credit: © Zack Frank - stock.adobe.com

Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing

Patrick Lavery
May 7th 2025
Article

The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.

Related Content
Regulatory Oversight
|
Analytics
|
Quality Systems
|
Laboratory Equipment and Instruments
Advertisement

A laboratory technician performing a quality control test on a batch of pharmaceutical tablets, highlighting the importance of ensuring drug safety. | Image Credit: ©MAY -stock.adobe.com

Poor API Quality Threatens a Healthy Supply

Susan Haigney
May 9th 2025
Article

Poor API quality may often lead to delays in production and a shortage of supply.


Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.


Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

New CBER Director Appointed

Susan Haigney
May 7th 2025
Article

FDA chooses Dr. Vinay Prasad, MD, MPH, a hematologist-oncologist, to lead the Center for Biologics Evaluation and Research at FDA.


Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.


n-nitrosodimethylamine molecular structure, 3d model molecule, n-nitrosamines, structural chemical formula view from a microscope | Image Credit: © Сергей Шиманович - stock.adobe.com

Strategies for Mitigating Nitrosamine Risk

Susan Haigney
May 7th 2025
Article

Amit Chivate, senior market manager, Greater Asia and China, Roquette, provides his perspective on FDA’s recommendations regarding nitrosamines.


White House | Image Credit: © Zack Frank - stock.adobe.com

Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing

Patrick Lavery
May 7th 2025
Article

The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.

Advertisement
Advertisement
Advertisement
x
About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.